uniQure (NASDAQ:QURE) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its stake in uniQure (NASDAQ:QURE) by 458.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 295,042 shares of the biotechnology company’s stock after acquiring an additional 242,214 shares during the quarter. Vontobel Holding Ltd. owned approximately 0.62% of uniQure worth $1,997,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 4,315 shares during the period. Raymond James & Associates increased its stake in shares of uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 3,145 shares in the last quarter. SG Americas Securities LLC acquired a new position in uniQure in the 4th quarter worth about $116,000. Harbor Capital Advisors Inc. boosted its position in uniQure by 21.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 5,389 shares in the last quarter. Finally, Hudson Bay Capital Management LP grew its holdings in uniQure by 66.0% in the third quarter. Hudson Bay Capital Management LP now owns 390,200 shares of the biotechnology company’s stock valued at $2,618,000 after purchasing an additional 155,100 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of uniQure stock opened at $4.67 on Friday. The business’s 50 day moving average price is $5.36 and its 200 day moving average price is $6.05. The company has a current ratio of 8.85, a quick ratio of 8.68 and a debt-to-equity ratio of 0.49. uniQure has a one year low of $4.61 and a one year high of $22.48.

uniQure (NASDAQ:QURE) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. The business had revenue of $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. As a group, research analysts forecast that uniQure will post -4.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright decreased their target price on uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Friday, March 1st. The Goldman Sachs Group downgraded shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Mizuho lowered their price objective on uniQure from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Monday, March 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $28.00 target price on shares of uniQure in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 27,904 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other uniQure news, COO Pierre Caloz sold 9,455 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at $554,110.21. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now owns 440,839 shares in the company, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. Insiders have sold 53,265 shares of company stock valued at $339,845 over the last ninety days. Company insiders own 4.05% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.